Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance
Authors:
Open Access
- 15 May 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (5) , e0126022
Abstract
Glioblastomas (GBM) are comprised of a heterogeneous population of tumor cells, immune cells, and extracellular matrix. Interactions among these different cell types and pro-/anti-inflammatory cytokines may promote tumor development and progression. The objective of this study was to develop a cytokine-related gene signature to improve outcome prediction for patients with primary GBM. Here, we used Cox regression and risk-score analysis to develop a cytokine-related gene signature in primary GBMs from the whole transcriptome sequencing profile of the Chinese Glioma Genome Atlas (CGGA) database (n=105). We also examined differences in immune cell phenotype and immune factor expression between the high-risk and low-risk groups. Cytokine-related genes were ranked based on their ability to predict survival in the CGGA database. The six genes showing the strongest predictive value were CXCL10, IL17R, CCR2, IL17B, IL10RB, and CCL2. Patients with a high-risk score had poor overall survival and progression-free survival. Additionally, the high-risk group was characterized by increased mRNA expression of M2 microglia/macrophage markers and elevated levels of IL10 and TGFβ1. The six cytokine-related gene signature is sufficient to predict survival and to identify a subgroup of primary GBM exhibiting the M2 cell phenotype.Keywords
This publication has 56 references indexed in Scilit:
- CNS macrophages and peripheral myeloid cells in brain tumoursActa Neuropathologica, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Using the molecular classification of glioblastoma to inform personalized treatmentThe Journal of Pathology, 2013
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2010
- Glioblastoma multiforme: a review of therapeutic targetsExpert Opinion on Therapeutic Targets, 2009
- Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomasThe Journal of Pathology, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor MicroenvironmentClinical Cancer Research, 2005
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.2001